AstraZeneca Sells Rights To Embattled Bipolar Drug For $35M

Law360 (December 4, 2019, 1:43 PM EST) -- AstraZeneca has agreed to sell the rights to its antipsychotic Seroquel in the U.S. and Canada for $35 million, in a move that offloads the bipolar drug at the center of recent litigation accusing the pharmaceutical giant of running a pay-for-delay scheme to block generic versions.

The British-Swedish company said Tuesday in documents filed with the U.S. Securities Exchange Commission that it will sell the commercial rights to Seroquel and Seroquel XR, used to treat schizophrenia and bipolar disorder, to German pharmaceutical company Cheplapharm Arzneimittel GmbH for $35 million and future payments up to $6 million.

Ruud Dobber, vice president of...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Attached Documents

Related Sections

Companies